Clinical Trials Logo

Essential Hypertension clinical trials

View clinical trials related to Essential Hypertension.

Filter by:

NCT ID: NCT04505618 Recruiting - Clinical trials for Diabetic Retinopathy

Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease

OCTA-RVD
Start date: October 1, 2019
Phase: N/A
Study type: Interventional

This study will perform a prospective, longitudinal analysis of clinical and imaging findings from normal controls and subjects with retinal vascular disease to better define the diagnostic imaging criteria that signify change in disease stage. This includes disease progression in early stages of disease or disease regression with appropriate standard-of-care treatment.

NCT ID: NCT04495231 Completed - Clinical trials for Diabetes Mellitus, Type 2

Sympathetic Activity and Cardiometabolic Complications

SYMPACT
Start date: September 1, 2007
Phase:
Study type: Observational

Recent studies on catecholamine physiology have shown a direct correlation with arterial hypertension, overcoming the exclusive role in the diagnosis and follow-up of chromaffin tumors. Nevertheless, in literature, few studies explore and reveal the utility of testing metanephrines for the evaluation of sympathetic activity and its associated cardiometabolic complications in patients with essential hypertension.

NCT ID: NCT04488978 Completed - Clinical trials for Essential Hypertension

Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension

Start date: May 21, 2020
Phase: Phase 2
Study type: Interventional

A Randomized, Double-blind, Multicenter, Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypertension

NCT ID: NCT04488289 Active, not recruiting - Clinical trials for Hypertension,Essential

The Föllinge Hypertension and Lifestyle Study

FIHST
Start date: February 1, 2021
Phase: N/A
Study type: Interventional

Ambulatory blood pressure measurement is more demanding in terms of technical equipment and specially trained staff. If blood pressure measurement in a self-care room is on average equivalent to the ambulatory blood pressure daytime monitoring of hypertension in primary care could be simplified. We therefore want to examine patients monitored for hypertension (ICD 10) with three different methods: conventional blood pressure measurement in office, self-directed automated measurement and ambulatory blood pressure, starting in December 2020. We will also offer an interview covering cardiovascular risk factors, at time for enrollment and after 6 months. The study was approved to include 150 adult study patients (The swedish ethical review authority 2020-01375), men and women, where diagnosis and treatment of hypertension is relevant after a clinical evaluation.

NCT ID: NCT04470830 Completed - Clinical trials for Essential Hypertension

A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea

Start date: September 11, 2019
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety by assessing all serious and non-serious adverse events (AEs), irrespective of relatedness or expectedness, as well as other safety parameters including laboratory values, serious adverse events (SAEs)/serious adverse drug reactions (ADRs), unexpected AEs and ADRs that are not reflected on the precaution in the use, ADRs already known, non-serious ADRs and other safety related information (laboratory values changes, etc).

NCT ID: NCT04470817 Completed - Clinical trials for Essential Hypertension

A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea

Start date: August 7, 2018
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety by determining the incidence rates of all adverse events (AEs) including serious adverse events (SAEs)/serious adverse drug reactions (ADRs), unexpected AEs and ADRs that are not reflected on the precaution in the use, ADRs already known, non-serious ADRs and other safety related information (laboratory values changes, etc).

NCT ID: NCT04460300 Recruiting - Clinical trials for Essential Hypertension

Effects of Aromatherapy in Hypertensive Individuals

Start date: December 3, 2018
Phase: N/A
Study type: Interventional

Objective: To investigate the effect of aromatherapy on blood pressure and stress response by inhalation and foot massage in individuals with essential hypertension. Methods: The randomized controlled trial is performed with 69 individuals diagnosed with essential hypertension hospitalized. There are two interventions (group 1: aromatherapy-inhalation method, group 2: aromatherapy-foot massage) and a control group in the study. Blood pressure is measured with a digital sphygmomanometer after 10 minutes of rest; stress response is determined by heart rate, blood cortisol levels and anxiety scale. Aromatherapy with lavender oil is applied to the intervention groups; no application is made to the control group and routine follow-up at the hospital continued.

NCT ID: NCT04459741 Completed - HIV-1-infection Clinical Trials

HIV, Immune Activation and Salt Sensitive Hypertension

HISH
Start date: January 2, 2019
Phase: N/A
Study type: Interventional

High dietary salt is associated with immune activation, elevated levels of inflammatory cytokines and hypertension in murine models. Hypertension is independently associated with inflammation in both murine studies and studies in humans. In people living with HIV, these interactions are not well established. The aim of this study is to determine the effect of excess dietary salt on immune cell activation, pro- and anti-inflammatory cytokines and blood pressure between individuals with and without hypertension among people living with HIV and HIV negative persons.

NCT ID: NCT04406129 Recruiting - Hypertension Clinical Trials

Effect of Gut Microbiome Restoration on Primary Hypertension Via FMT

FMT
Start date: March 17, 2021
Phase: Early Phase 1
Study type: Interventional

Mounting preclinical and clinical evidences have proved the causal role of gut microbiota on the pathogenesis of primary hypertension. Restoration of gut microbiota ameliorated high BP in rodents and/or human cases.A hypothesis is thus raised that gut microbiome restoration can be a potential approach to ameliorate hypertension. This pilot study will utilize fecal microbiota transplantation (FMT) capsules, in comparison with placebo capsules, to investigate the effect, safety and underlying mechanisms of gut microbiome restoration on primary hypertension.

NCT ID: NCT04403347 Recruiting - Hypertension Clinical Trials

Effect of Gut Microbiome Restoration on Primary Hypertension Via Dietary Intervention

Start date: July 8, 2021
Phase: Early Phase 1
Study type: Interventional

Mounting preclinical and clinical evidences have proved the optimal role of diets (i.e. DASH (Dietary Approaches to Stop Hypertension) diet, Mediterranean diet) on BP control and a causal role of gut microbiota on the pathogenesis of primary hypertension. Dietary changes appeared to reshape gut microbiota and to ameliorate diseases such as Type 2 Diabetes. A hypothesis is thus raised that dietary changes can be a potential approach to ameliorate hypertension via gut microbiome restoration. This pilot study will utilize an innovative natural dietary formulation (patent ID: CN110250417A), in comparison with classic antihypertensive treatment (losartan 50mg per day) and usual care (guideline-based patient education and lifestyle recommendations), to investigate its effect and safety on primary hypertension treatment, and the underlying mechanisms of gut microbiome restoration.